Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone.
Since deleterious effects of m-CPP, the primary catabolic metabolite of trazodone, were last reviewed 2 years ago, research data continue to accrue showing that clinically significant levels of m-CPP (a) are generated in patients using trazodone for sleep and (b) are present 24 h a day and (c) have potentially serious ill effects. This commentary argues that the documented potential for harm and multiple risks of m-CPP outweigh potential benefits of trazodone, given the development and marketing of many safer alternatives since trazodone's introduction in the 1980s.
Kast
Richard E
RE
Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA. rekast@email.com
D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001007:Anxiety / Q000139:chemically induced / Q000503:physiopathology; D001711:Biotransformation; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D051379:Mice; D010200:Panic / Q000187:drug effects / Q000502:physiology; D010879:Piperazines / Q000009:adverse effects / Q000097:blood*; D044403:Receptor, Serotonin, 5-HT2B / Q000187:drug effects / Q000502:physiology; D044405:Receptor, Serotonin, 5-HT2C / Q000187:drug effects / Q000502:physiology; D012307:Risk Factors; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000097:blood*; D013329:Structure-Activity Relationship; D014196:Trazodone / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use
D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D044403:Receptor, Serotonin, 5-HT2B; D044405:Receptor, Serotonin, 5-HT2C; D017366:Serotonin Receptor Agonists; C015068:1-(3-chlorophenyl)piperazine; D014196:Trazodone